In prostate cancer, androgen receptor spliced variants (AR‐Vs) have been implicated in the carcinogenesis of metastatic prostate cancer, which contribute to resistance to both anti‐androgen therapy and radiotherapy.85 This evidence concerns the gene AR and metastatic prostate carcinoma.